Last Updated : July 28, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Invega | Paliperidone | Schizophrenia | Do not list | Complete | ||
| Invega Sustenna | Paliperidone palmitate | Schizophrenia | Do not list | Complete | ||
| Invokamet | Canagliflozin and metformin hydrochloride | diabetes mellitus, type 2 | Reimburse with clinical criteria and/or conditions | Complete | ||
| Invokana | Canagliflozin | Diabetes mellitus, type 2 | List with criteria/condition | Complete | ||
| Invokana | Canagliflozin | Diabetes Mellitus, Type 2 | Withdrawn | |||
| Iressa | Gefitinib | Cancer, Lung , non-small cell | Do not list | Complete | ||
| Isentress | Raltegravir | HIV | List with clinical criteria and/or conditions | Complete | ||
| Isentress | Raltegravir | HIV (treatment naïve) | Do not list | Complete | ||
| Istodax | Romidepsin | Peripheral T-Cell Lymphoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Isturisa | osilodrostat | Endogenous Cushing’s syndrome | Suspended |
Last Updated : July 28, 2024